This research service covers the pharmaceutical industry development pipeline for diabetes mellitus in the United States, with 2005 as the base year. Included are both the products projected to enter the market by the end of the forecast coverage period in 2012, as well as products entering the market in 2005 that correspond to the in-depth discussion drug classes. The focus of this piece is on pipeline technology developments and has greater focus on: GLP-1 Agonists, DPP-IV Inhibitors; PPAR Modulators; and Pulmonary Insulin. Also discussed are pipeline developments in other areas of oral antidiabetic drugs, injectables, and insulins other than pulmonary. Product Analysis charts are included for those products in Phase III clinical trials.
Executive Summary
- Introduction
Research Scope and Methodology
- Scope and Segmentation
- Research Methodology
Diabetes Overview
- Introduction
- Types of Diabetes
- Prevalence
- Incidence
- Current Treatment
Pipeline Competitive Analysis
- Introduction
- Key Pipeline Companies
- Areas of Opportunity
Introduction
GLP-1 Agonists Pipeline Analysis
Introduction
Pulmonary Insulin Analysis
Introduction
DPP-IV Pipeline Analysis
Introduction
PPAR Pipeline Analysis
Introduction
Pipeline Overviews
Decision Support Databases
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Industries | Healthcare |
| WIP Number | N097-01-00-00-00 |
| Is Prebook | No |
U.S. Diabetes Pipeline Outlook
22-Nov-2006
North America
Market Research